Top Markets
#1 Seeker Seeker +45.46%
#2 Helium Helium +36.27%
#3 TENDIES TENDIES +29.33%
#4 Pons Pons +28.89%
#5 pipedog pipedog +20.31%
#6 UnifAI Network UnifAI Network +19.15%
#7 Zylo Ecosystem Zylo Ecosystem +19.08%
#8 Bounce Bounce +18.99%
#9 ZKsync ZKsync +14.63%
#10 Zora Zora +14.14%
Coin of the day
Seeker Seeker
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Classificação em ações #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Preço da ação
$9.50
Última sincronização: 2025-01-08
Valor de mercado
$819.52M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Poseida Therapeutics, Inc. (PSTX)

Categoria

Healthcare
Receita da Poseida Therapeutics, Inc. (PSTX)
Receita em Sep 2024 TTM: $150.86M
De acordo com os últimos relatórios financeiros da Poseida Therapeutics, Inc., a receita atual da empresa (TTM) é $150.86M. Em 2022, a empresa obteve uma receita de $130.36M um aumento em relação a a receita do ano 2021, que foi de $31.24K. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Poseida Therapeutics, Inc. de 2016 a 2026
Receita no final de cada ano
Ano Receita Alterar
2026 (TTM) $150.86M 133.15%
2023 $64.70M -50.37%
2022 $130.36M 417,217.08%
2021 $31.24K 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 -100.00%
2017 $2.99M -69.44%
2016 $9.77M 0.00%
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 8,268.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 3,891.36%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 10,336.52%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 1,376.89%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH